MedTrace Logo

Ketorolac on Posterior Thoracolumbar Spinal Fusions

NCT03278691 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 600

Last updated 2023-04-20

No results posted yet for this study

Summary

To determine is low-dose ketorolac use in the early post-operative period (within 48 hours) provides adequate analgesia without long term adverse effect on spinal fusion rates when compared to post-operative analgesia without the use of NSAIDs.

Conditions

  • Thoracolumbar Spinal Fusions

Interventions

DRUG

Saline

1 ml saline IV Q6H

DRUG

Ketorolac

15 mg (15 mg/ml) IV Q6H

Sponsors & Collaborators

  • Henry Ford Health System

    lead OTHER

Principal Investigators

  • Doris Tong, MD · Michigan Spine and Brain Surgeons

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-10-03
Primary Completion
2023-12-31
Completion
2025-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03278691 on ClinicalTrials.gov